HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries.
about
Programmatic feasibility of dried blood spots for the virological follow-up of patients on antiretroviral treatment in Nord Kivu, Democratic Republic of the CongoChallenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell countHIV drug resistance early warning indicators in Namibia for public health actionHIV drug resistance early warning indicators in namibia with updated World Health Organization guidanceMonitoring HIV Drug Resistance Early Warning Indicators in Cameroon: A Study Following the Revised World Health Organization RecommendationsAssessment of the World Health Organization's HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in NamibiaGlobal epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort studyDeclining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings.Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts.Gender-specific risk factors for virologic failure in KwaZulu-Natal: automobile ownership and financial insecurity.Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania.Monitoring prevention or emergence of HIV drug resistance: results of a population-based foundational survey of early warning indicators in mainland TanzaniaUpdate on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011Predictors of poor retention on antiretroviral therapy as a major HIV drug resistance early warning indicator in Cameroon: results from a nationwide systematic random sampling.An analysis of drug resistance among people living with HIV/AIDS in Shanghai, ChinaSharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillanceDevelopment of antiretroviral resistance in children with HIV in low- and middle-income countriesEvolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionGlobal trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat" policy of the World Health Organization?First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.Scaling-up health information systems to improve HIV treatment: An assessment of initial patient monitoring systems in Mozambique.Programmatic and ethical challenges in the implementation of treatment-as-prevention in the context of HIV and drug-resistant tuberculosis co-infection in sub-Saharan Africa.Sociodemographic profile and predictors of outpatient clinic attendance among HIV-positive patients initiating antiretroviral therapy in Selangor, Malaysia.Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.Viraemia before, during and after pregnancy in HIV-infected women on antiretroviral therapy in rural KwaZulu-Natal, South Africa, 2010-2015.Results from implementing updated 2012 World Health Organization Guidance on early-warning indicators of HIV drug resistance in Zimbabwe.Results of early warning indicators for HIV/AIDS in 42 outpatient clinics in 25 northern provinces of Vietnam.
P2860
Q27312774-FBFD6A57-EA47-4963-9C65-8A054C159592Q27318314-3A5207B9-5F07-44BA-8793-0F32D1E3BFF1Q28533732-0B8A0932-0017-4DB6-A5F7-AC490917995AQ28540264-F67632D0-661D-4E45-A778-446F0EA40AB7Q28548432-22F2A774-B6F2-4DBA-80B2-A087FCA0BC25Q28554721-F6058254-105C-4C0A-ACA7-FEF737BAF3FBQ30384060-5FA2F273-2482-434F-8E45-481232F7B56CQ31114921-C0D16606-BCC8-4DD7-A63E-59592276378CQ33787631-355F2972-B3F5-4420-AE8D-BBBEB0F1043AQ34345205-FEDE9535-0981-41DA-9B23-656B7E2828EBQ34707535-C4570A6C-F476-4199-8F61-B65E9996A412Q35146148-04847958-EA31-4540-97B3-39DE9F4DD90BQ35917578-DDDBA4B1-B0BE-4A76-BE6A-750EA6B43876Q36193256-A06F0D5B-77E0-43F8-A320-2FEF864166F0Q36277181-E77E3446-B4C0-42A6-A7E6-67DFC3550E66Q36794795-9C85129F-604E-451A-B262-C23A13BA9E74Q36852631-7B1CFBD3-494D-4A3B-8D9B-FBC99340DDF5Q37071435-3BED8056-8D44-4F01-8BB5-80313C6BCD75Q37216235-F82EB63E-6F96-4E34-AFD7-955B2015A60CQ37326870-50DF326F-7013-4EAE-84E5-6F9CF9B54B58Q37403995-7CF1A7A5-D671-4D2D-B542-2B51AB09607FQ37642995-9CFDEC87-CC6E-4D93-80F8-664282F92F64Q37732266-F6A2A170-D993-408D-9FB4-7E91BF480257Q38375251-CE988A0D-6DAD-4E3F-95B7-D3DD607BE3D0Q38393167-A9E93DA8-5DD4-475A-A5FB-9B90DBC6BB5EQ38631497-DC32EBAF-12CE-4A07-9401-9C9228AEEB62Q41219268-24ACB6A9-242E-407F-BB36-9772FC5E987DQ46187732-973A4D62-AA5E-4DDD-A90A-AC3AA7BDF669Q55253423-A2C8826A-99B7-40DA-B465-6BB3E4E60BCEQ55363358-BD9778BE-907B-4EB6-8392-320C7CFB4859
P2860
HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
HIV drug resistance early warn ...... obal report from 50 countries.
@ast
HIV drug resistance early warn ...... obal report from 50 countries.
@en
type
label
HIV drug resistance early warn ...... obal report from 50 countries.
@ast
HIV drug resistance early warn ...... obal report from 50 countries.
@en
prefLabel
HIV drug resistance early warn ...... obal report from 50 countries.
@ast
HIV drug resistance early warn ...... obal report from 50 countries.
@en
P2093
P2860
P921
P356
P1476
HIV drug resistance early warn ...... obal report from 50 countries.
@en
P2093
Ahmed Saadani
Diane E Bennett
Giovanni Ravasi
James H McMahon
Karen F Kelley
Michael R Jordan
Silvia Bertagnolio
Steven Y Hong
P2860
P304
P356
10.1093/CID/CIS207
P407
P478
54 Suppl 4
P577
2012-05-01T00:00:00Z